Actinogen is advancing a revolutionary oral therapeutic, Xanamem^®, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation.

ACW at Sachs Neuroscience & JPM week in San Francisco

The ACW senior executive team are attending the Sachs Associates 9th Annual Neuroscience Innovation Forum and holding meetings associated with the 44th Annual JP Morgan Healthcare Conference (JPM Week) in San Francisco. 

The presentation attached to the announcement summarises recent advances in the Xanamem AD program and the multiple, independent clinical trials supporting the likelihood of success in the current XanaMIA pivotal trial. The trial is due to report the outcome of its interim analysis in late January 2026 and final topline results in November 2026.

Final, 246th participant randomized in XanaMIA AD trial – topline results Nov 2026

ACW has announced the enrolment and start of treatment for the final participant in the XanaMIA phase 2b/3 Alzheimer’s disease trial. This means that topline, final results will be available in November 2026. Interim results are expected at the end of January 2026.

ACW is holding a live webinar & Q&A session 18 December 2025 at 11am Sydney time. Click HERE to register and join the live event, or to watch a replay after the event.

ACW CEO & CFO present at Bell Potter Healthcare conference

ACW CEO, Dr Steven Gourlay and CFO, Mr Will Souter, presented at the Bell Potter Healthcare Conference 2025

ACW 2025 AGM - Chair's address & CEO's presentation

Actinogen has released the Chair’s address and CEO’s slide presentation for its 2025 Annual General Meeting held 19 November 2025.

Click here to view AGM voting results

Actinogen receives positive recommendation from first Data Monitoring Committee Meeting to continue Alzheimer's phase 2b/3 trial without amendment.

ACW is pleased to announce the positive outcome of the first meeting of its XanaMIA phase 2b/3 trial’s independent Data Monitoring Committee (DMC) to continue the trial without amendment.

ACW Progress Update and Q&A Webinar

ACW held a progress update and Q&A webinar on 28 October 2025. The leadership team, led by CEO, Dr Steven Gourlay outlined the company’s significant progress over recent months and discuss key upcoming milestones. 

A recording of the webinar is now available on Actinogen’s YouTube channel.